Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical PBSCT for High-Risk AML in First Remission
NCT00101140Phase 2Withdrawn
- Sponsor
- Eastern Cooperative Oncology Group
- Modality
- Stem Cell Therapies
01
Overview
A Phase 2 trial of allogeneic peripheral blood progenitor cells in acute myeloid leukemia (AML), sponsored by Eastern Cooperative Oncology Group. Status: withdrawn.
02
Drugs
allogeneic peripheral blood progenitor cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00101140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00101140.